AstraZeneca chose KPR, New York, to handle ad duties for its superstatin, a cholesterol-lowering drug yet to be approved by the FDA, sources familiar with the decision said. Other finalists in the review were CommonHealth
's Quantum Group, Parsippany, N.J., and a joint effort between Lally McFarland & Pantello and Jordan McGrath Case & Partners/Euro RSCG, both New York. Billings were not determined.
Copyright December 2000, Crain Communications Inc.